(ACB) Aurora Cannabis - Overview
Stock: Cannabis, Oils, Capsules, Edibles, Concentrates
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 88.1% |
| Relative Tail Risk | -22.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.53 |
| Alpha | -54.37 |
| Character TTM | |
|---|---|
| Beta | 1.306 |
| Beta Downside | 1.197 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.60% |
| CAGR/Max DD | -0.39 |
Description: ACB Aurora Cannabis January 01, 2026
Aurora Cannabis Inc. (NASDAQ:ACB) is a vertically integrated cannabis producer headquartered in Edmonton, Canada. It operates two segments-Canadian Cannabis and Plant Propagation-offering a broad portfolio that spans pharmaceutical-grade medical products, consumer-focused dried flower, oils, concentrates, edibles, vaporizers, topicals, and plant propagation services. Its brand lineup includes domestic names such as San Rafael ’71, Greybeard, and Aurora, as well as international labels like Pedanios and CraftPlant.
As of FY 2023, Aurora generated roughly $1.3 billion in revenue but posted a net loss of about $1.0 billion, reflecting ongoing cost-structure challenges and price compression in the Canadian market. The company’s production capacity now exceeds 100,000 kg of dried flower per year, and its cash balance sits near $350 million, giving it limited runway without further financing. Key economic drivers include the pace of Canadian regulatory reforms (e.g., potential expansion of adult-use retail), the opening of U.S. medical markets, and the broader macro trend of cannabis legalization that continues to lift demand forecasts across North America.
For a deeper, data-driven view of Aurora’s valuation and risk profile, you might explore the analytical tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 70.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 5.14 > 1.0 |
| NWC/Revenue: 84.40% < 20% (prev 104.0%; Δ -19.56% < -1%) |
| CFO/TA 0.00 > 3% & CFO 2.24m > Net Income 70.5m |
| Net Debt (-80.3m) to EBITDA (106.9m): -0.75 < 3 |
| Current Ratio: 3.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.8m) vs 12m ago -1.00% < -2% |
| Gross Margin: 72.90% > 18% (prev 0.55%; Δ 7235 % > 0.5%) |
| Asset Turnover: 45.40% > 50% (prev 36.70%; Δ 8.70% > 0%) |
| Interest Coverage Ratio: 10.24 > 6 (EBITDA TTM 106.9m / Interest Expense TTM 8.27m) |
Altman Z'' -15.00
| A: 0.40 (Total Current Assets 423.8m - Total Current Liabilities 124.1m) / Total Assets 756.9m |
| B: -8.46 (Retained Earnings -6.41b / Total Assets 756.9m) |
| C: 0.11 (EBIT TTM 84.6m / Avg Total Assets 782.2m) |
| D: -33.76 (Book Value of Equity -6.41b / Total Liabilities 189.8m) |
| Altman-Z'' Score: -59.71 = D |
Beneish M -3.24
| DSRI: 0.97 (Receivables 46.7m/40.1m, Revenue 355.1m/296.3m) |
| GMI: 0.75 (GM 72.90% / 54.96%) |
| AQI: 0.66 (AQ_t 0.09 / AQ_t-1 0.14) |
| SGI: 1.20 (Revenue 355.1m / 296.3m) |
| TATA: 0.09 (NI 70.5m - CFO 2.24m) / TA 756.9m) |
| Beneish M-Score: -3.24 (Cap -4..+1) = AA |
What is the price of ACB shares?
Over the past week, the price has changed by -14.29%, over one month by -17.92%, over three months by -20.18% and over the past year by -44.32%.
Is ACB a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.4 | 83.6% |
| Analysts Target Price | 6.4 | 83.6% |
| ValueRay Target Price | 2.7 | -21.3% |
ACB Fundamental Data Overview February 03, 2026
P/E Forward = 24.1546
P/S = 0.6257
P/B = 0.5847
Revenue TTM = 355.1m CAD
EBIT TTM = 84.6m CAD
EBITDA TTM = 106.9m CAD
Long Term Debt = 40.2m CAD (from longTermDebt, last fiscal year)
Short Term Debt = 59.8m CAD (from shortLongTermDebt, last quarter)
Debt = 104.0m CAD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -80.3m CAD (from netDebt column, last fiscal year)
Enterprise Value = 322.1m CAD (313.9m + Debt 104.0m - CCE 95.7m)
Interest Coverage Ratio = 10.24 (Ebit TTM 84.6m / Interest Expense TTM 8.27m)
EV/FCF = -17.59x (Enterprise Value 322.1m / FCF TTM -18.3m)
FCF Yield = -5.68% (FCF TTM -18.3m / Enterprise Value 322.1m)
FCF Margin = -5.16% (FCF TTM -18.3m / Revenue TTM 355.1m)
Net Margin = 19.84% (Net Income TTM 70.5m / Revenue TTM 355.1m)
Gross Margin = 72.90% ((Revenue TTM 355.1m - Cost of Revenue TTM 96.2m) / Revenue TTM)
Gross Margin QoQ = 89.57% (prev 89.57%)
Tobins Q-Ratio = 0.43 (Enterprise Value 322.1m / Total Assets 756.9m)
Interest Expense / Debt = 1.87% (Interest Expense 1.94m / Debt 104.0m)
Taxrate = 2.62% (841.0k / 32.1m)
NOPAT = 82.4m (EBIT 84.6m * (1 - 2.62%))
Current Ratio = 3.41 (Total Current Assets 423.8m / Total Current Liabilities 124.1m)
Debt / Equity = 0.20 (Debt 104.0m / totalStockholderEquity, last quarter 531.9m)
Debt / EBITDA = -0.75 (Net Debt -80.3m / EBITDA 106.9m)
Debt / FCF = 4.38 (negative FCF - burning cash) (Net Debt -80.3m / FCF TTM -18.3m)
Total Stockholder Equity = 555.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.01% (Net Income 70.5m / Total Assets 756.9m)
RoE = 12.68% (Net Income TTM 70.5m / Total Stockholder Equity 555.7m)
RoCE = 14.20% (EBIT 84.6m / Capital Employed (Equity 555.7m + L.T.Debt 40.2m))
RoIC = 13.39% (NOPAT 82.4m / Invested Capital 615.8m)
WACC = 8.51% (E(313.9m)/V(417.8m) * Re(10.73%) + D(104.0m)/V(417.8m) * Rd(1.87%) * (1-Tc(0.03)))
Discount Rate = 10.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 8.43%
Fair Price DCF = unknown (Cash Flow -18.3m)
EPS Correlation: 55.69 | EPS CAGR: 319.1% | SUE: -0.39 | # QB: 0
Revenue Correlation: 88.31 | Revenue CAGR: 10.53% | SUE: 0.07 | # QB: 0
EPS next Year (2027-03-31): EPS=0.07 | Chg30d=-0.040 | Revisions Net=-1 | Growth EPS=+107.7% | Growth Revenue=+5.3%